Latest Breaking News On - Alexander lobo - Page 1 : vimarsana.com

Inhibikase Therapeutics, Inc (NASDAQ:IKT) Q1 2024 Earnings Call Transcript

Operator: Greetings and welcome to Inhibikase Therapeutics First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Red whiteAlexander loboGarth lees rolfeMilton wernerInhibikase therapeutics incNational institutes of healthNational institute of neurological diseaseDivision of cardiologyOffice of cardiologyNational cancer instituteInhibikase therapeuticsCall transcript mayInhibikase therapeutics first quarterResults conferenceStern investorChief executive officer

Between The Lines at the New Diorama Theatre

Between The Lines at the New Diorama Theatre
londontheatre1.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from londontheatre1.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomTina torbeyVali wrightAndrew brownJack baxterPauline mcgrathAlexander lobo morenoNassy konanHughbert andrew brownMarcus reissJake waldenMaggie norrisChristopher neelsJames meteyardAlex forey

Aileron Therapeutics, Inc : Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients'

United statesAlexander loboLiz meloneExchange commissionDrug administrationComputershare trust company incNasdaq capital marketComputershare trust companyPrivate securities litigation reform actUnited states food

Aileron Therapeutics (ALRN) Presents Strong Results from Phase 1 Study of ALRN-6924

Aileron Therapeutics (ALRN) Presents Strong Results from Phase 1 Study of ALRN-6924
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesManuel aivadoAlexander loboAllen annisLiz meloneExchange commissionResearch at aileronAileron therapeutics incInternational conference on molecularDrug administrationMolecular targetsCancer therapeuticsBarcelona octoberCell cycle arrestBone marrow stem cellsHair follicles

Aileron Therapeutics Presents Results from Phase 1 Study in

p53-mediated cell cycle arrest results demonstrate potential of ALRN-6924 to prevent chemotherapy-induced neutropenia, thrombocytopenia, and anemia, as.

United statesManuel aivadoAlexander loboAllen annisLiz meloneExchange commissionResearch at aileronInternational conference on molecularDrug administrationMolecular targetsCancer therapeuticsBarcelona octoberCell cycle arrestBone marrow stem cellsHair folliclesDose dependent degree